UniQure (NASDAQ:QURE) is one of the promising stocks to buy under $50. On December 11, Stifel lowered the firm’s price target ...
Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces ...
Most of the original Israeli investors - mainly OrbiMed and Pontifax Venture Capital - exited around the IPO, and as far as ...
The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...
Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –– Unaudited 2025 total product and royalty revenue of ...
Hou Wey Fook is confident that AI-related optimism is based on sound fundamentals Read more at The Business Times.
FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and ...
The West Virginia Division of Natural Resources announced Monday the agency will start a new citizen project to track the ...
General Hospital spoilers and updates for the week of January 12 tease Brad Cooper’s (Parry Shen) overprotective, Willow Cain ...
6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback